默沙东联合Surface开展联合疗法研究,或将改善K药耐药性

2021-04-04 秘丛丛 亿欧

默沙东的“摇钱树“K药找到了另一个合作伙伴。

默沙东的“摇钱树“K药找到了另一个合作伙伴。

3月9日,默沙东和Surface Oncology(下称:Surface)达成了一项合作协议:将联合K药(Keytruda)与Surface的靶向IL-27的抗体疗法(SRF388),评估双方结合后的安全性和有效性。该研究针对实体瘤患者,特别是患有肝癌和肾癌的患者。其中,K药已于2007获得FDA的批准。

Surface是一家临床阶段免疫肿瘤学公司,致力于开发针对肿瘤微环境的下一代免疫疗法。该公司于2018年4月在纳斯达克证券交易所上市。“ Surface是唯一一家靶向IL-27做临床研究的公司,我们相信这种细胞因子可能在缓解PD-1抑制剂的耐药性中发挥重要作用。”Surface的CEO Rob Ross表示。

该公司表示,SRF388临床前研究表明,它可阻断IL-27的免疫抑制生物学作用,能与其他抗癌药物(包括抗PD- 1抑制剂)以及作为单一疗法有效治疗肿瘤。去年11月,Surface宣布SRF388被FDA授予“孤儿药”并进入审批“快速通道”,用于治疗肝细胞癌。其还公布,SRF388已获得临床I期的初步结果,有望在今年上半年公布。

其团队主要研究肿瘤微环境,开发多种抗体免疫疗法候选药物,改善癌症患者的预后。目前,Surface药物研发管线主要包括临床开发阶段的项目SRF617(CD39抗体)和SRF388(IL-27抗体),以及临床前项目SRF114(CCR8抗体)。其研发管线涉及4个关键作用机制:激活巨噬细胞、激活自然杀伤细胞、抑制或耗尽调节性T细胞、阻断细胞因子和代谢产物等抑制性细胞信号分子。

这并不是它和默沙东的首次合作,去年5月,双方达成了一项关于PD-1抗体与SRF617项目的联合治疗合作,大量研究支持CD39在使癌症逃避免疫反应方面发挥了作用。值得注意的是,SRF617是首批进入临床的CD39抗体之一。

此外,Surface还分别与诺华和葛兰素史克达成合作关系。2016年,Surface Oncology与诺华达成合作——诺华自此拥有Surface的全人源化CD73抗体SRF373的全球独家许可权。去年12月,它与GSK达成了一项协议,将其临床前项目SRF813,一款靶向PVRIG (CD112R)的全人源IgG1抗体的全球开发和商业化权利独家授权给GSK。

根据默沙东最新披露的财报,2020年,Keytruda全球销售额增长30%,达到143.80亿美元。目前,默沙东通过FDA批准的适应症多达20余种,覆盖从黑色素瘤到宫颈癌等适应症。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647001, encodeId=1856164e001cd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Fri Sep 17 09:39:16 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656053, encodeId=6d1d1656053bc, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Oct 31 03:39:16 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956814, encodeId=8b77195681499, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Fri Aug 06 12:39:16 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259987, encodeId=f435125998ec0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618737, encodeId=ee0d1618e3789, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953777, encodeId=c734953e775b, content=新的疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Apr 04 16:52:15 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647001, encodeId=1856164e001cd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Fri Sep 17 09:39:16 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656053, encodeId=6d1d1656053bc, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Oct 31 03:39:16 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956814, encodeId=8b77195681499, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Fri Aug 06 12:39:16 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259987, encodeId=f435125998ec0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618737, encodeId=ee0d1618e3789, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953777, encodeId=c734953e775b, content=新的疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Apr 04 16:52:15 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
    2021-10-31 shanyongle
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647001, encodeId=1856164e001cd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Fri Sep 17 09:39:16 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656053, encodeId=6d1d1656053bc, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Oct 31 03:39:16 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956814, encodeId=8b77195681499, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Fri Aug 06 12:39:16 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259987, encodeId=f435125998ec0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618737, encodeId=ee0d1618e3789, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953777, encodeId=c734953e775b, content=新的疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Apr 04 16:52:15 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647001, encodeId=1856164e001cd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Fri Sep 17 09:39:16 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656053, encodeId=6d1d1656053bc, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Oct 31 03:39:16 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956814, encodeId=8b77195681499, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Fri Aug 06 12:39:16 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259987, encodeId=f435125998ec0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618737, encodeId=ee0d1618e3789, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953777, encodeId=c734953e775b, content=新的疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Apr 04 16:52:15 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
    2021-04-05 yese
  5. [GetPortalCommentsPageByObjectIdResponse(id=1647001, encodeId=1856164e001cd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Fri Sep 17 09:39:16 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656053, encodeId=6d1d1656053bc, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Oct 31 03:39:16 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956814, encodeId=8b77195681499, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Fri Aug 06 12:39:16 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259987, encodeId=f435125998ec0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618737, encodeId=ee0d1618e3789, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953777, encodeId=c734953e775b, content=新的疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Apr 04 16:52:15 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1647001, encodeId=1856164e001cd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Fri Sep 17 09:39:16 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656053, encodeId=6d1d1656053bc, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun Oct 31 03:39:16 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956814, encodeId=8b77195681499, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Fri Aug 06 12:39:16 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259987, encodeId=f435125998ec0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618737, encodeId=ee0d1618e3789, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Mon Apr 05 16:39:16 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953777, encodeId=c734953e775b, content=新的疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Sun Apr 04 16:52:15 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
    2021-04-04 SR~young海东

    新的疗法

    0

相关资讯

这四种癌症,早期发现或能控制!

有很多癌症类型若能在早期发现、积极控制,患者病情都能得到良好的治疗,甚至是可以达到临床治愈的标准,特别是以下四种癌症。

国产宫颈癌疫苗落地,关于它你不知道的都在这里

3月26日,国产宫颈癌二价疫苗在北京启动第一针接种。宫颈癌疫苗,是女性远离宫颈癌有效的工具。

Libtayo提高了宫颈癌患者的生存率!

赛诺菲和Regeneron的PD-1抑制剂Libtayo在晚期宫颈癌的III期临床试验中显示出阳性的总体生存(OS)结果。

Inovio宣布DNA免疫疗法治疗宫颈癌变创新药III期临床成功

Inovio宣布了一项针对宫颈癌前病变的VGX-3100首个III期临床试验的积极结果,在此项多中心、随机、双盲、安慰剂对照临床 III 期试验中,针对全部可评估受试者达到临床疗效的主要终点和所有次要

Br J Cancer:LIMCH1和HLA-DQB1为侵袭性宫颈癌的潜在标志物

宫颈癌是全球女性中的第四大癌症类型,且造成每年超过311,000名患者致命。大多数的癌症相关死亡与该疾病一级治疗后出现的肿瘤转移或疾病的复发相关。